Choi once reported that bladder cancer with mutation of RB1 and NFE2L2 can be enriched into basal subtype of muscle-invasive bladder cancer (Choi et al., 2017), which could be divided into epithelial–basal and more clinically aggressive mesenchymal subtypes (Guo et al., 2019). This evidence concerns the gene NFE2L2 and urinary bladder cancer.